Mylan (NASDAQ:MYL) received a $50.00 price target from equities research analysts at Deutsche Bank in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the stock. Deutsche Bank’s price target suggests a potential upside of 8.41% from the company’s current price.
Several other brokerages also recently weighed in on MYL. TheStreet upgraded Mylan from a “c” rating to a “b-” rating in a report on Wednesday, January 17th. Wells Fargo & Co set a $43.00 price target on Mylan and gave the stock a “hold” rating in a report on Thursday, January 18th. Zacks Investment Research upgraded Mylan from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Goldman Sachs Group upped their price target on Mylan from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, January 11th. Finally, Citigroup restated a “buy” rating and set a $58.00 price target (up previously from $48.00) on shares of Mylan in a report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Mylan currently has a consensus rating of “Buy” and an average target price of $44.14.
Mylan (NASDAQ MYL) traded down $0.73 during mid-day trading on Wednesday, hitting $46.12. The company had a trading volume of 5,956,241 shares, compared to its average volume of 6,580,000. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The stock has a market cap of $25,130.00, a P/E ratio of 27.78, a PEG ratio of 1.51 and a beta of 1.38. Mylan has a 52-week low of $29.39 and a 52-week high of $47.82.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.69% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. raised its stake in shares of Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after buying an additional 1,475 shares in the last quarter. BT Investment Management Ltd purchased a new position in shares of Mylan during the 3rd quarter worth approximately $142,000. Doliver Capital Advisors LP purchased a new position in shares of Mylan during the 2nd quarter worth approximately $201,000. Charter Trust Co. purchased a new position in shares of Mylan during the 4th quarter worth approximately $226,000. Finally, Parametrica Management Ltd purchased a new position in shares of Mylan during the 3rd quarter worth approximately $224,000. 75.07% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Mylan (MYL) Given a $50.00 Price Target at Deutsche Bank” was originally reported by American Banking and Market News and is owned by of American Banking and Market News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/24/mylan-myl-given-a-50-00-price-target-at-deutsche-bank.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
